Hengrui Pharmaceutical 4 products are included in the health insurance

On the evening of December 29th, Jiangsu Hengrui Pharmaceutical Co., Ltd. (here called Hengrui Pharmaceuticals) announced that the company's products were successfully negotiated with Karelli pearl monoanti, hydrochloric acid ascetamine injections and permendonase injections, and were included or retained in the National The scope of category B of the Health Insurance Directory, the agreement is valid from March 1, 2021 to December 31, 2022, injection of yew alcohol (albumin binding type) as the second batch of national organization drugs centralized procurement of selected drugs, included in the National Health Insurance Directory category B scope.
price, the announcement shows that the standard payment for ascetamine injections of hydrochloric acid is 91.8 yuan (2 ml:50mg/branch) and the standard payment standard for Pymendonase injections is 1477.7 yuan (2ml:1500IU/branch) and 2980 yuan (5ml:3750IU/branch).
announcement, hydrochloric acid ascetamine injection is a nervous system drug, injection with karelli pearl monoanti, pire winter enzyme injection and injection with yew alcohol (albumin binding type) are anti-tumor drugs and immunomodulators, of which the injection of karelli bead monoanti is a humanized anti-PD-1 monoclonal antibody.
is worth noting that Hengrui Pharmaceutical Karelli Pearl Single Resistance has been approved for 4 kinds of adaptive disorders, known by the industry as the most extensive range of domestic products.
the E drug manager reported that Hengrui Pharmaceutical's Carelli Pearl single resistance from the original 19,800 yuan per unit to 3000 yuan, not counting charitable gifts, a decrease of 85%.
Hengrui Pharmaceuticals said that the above-mentioned four products included in the National Health Insurance Directory, the total sales in 2019 is about 3.2 billion yuan, the total sales in the first three quarters of 2020 is about 4.8 billion yuan.
" company's above four products into the National Health Insurance Directory, will be conducive to the sale of products, the impact on the company's operating performance can not be estimated.
new version of the Health Insurance Directory will be officially implemented on March 1, 2021 and will not have a material impact on the Company's operating results for the reporting period.
it is understood that in 2018, the National Health Insurance Administration was established at the beginning of the organization of anti-cancer drugs special access negotiations, the final 17 drug negotiations successfully included in the catalog, and the agreement expires at the end of this year.
of the 17 anti-cancer drugs, three generic drugs were listed in Class B management.
14 exclusive drugs were renewed or renegotied on a rule-by-rule basis, with an average decline of 14.95 per cent, with individual first-line cancer drugs falling by more than 60 per cent.
estimates, 14 anti-cancer drugs reduced prices, is expected to save cancer patients more than 3 billion yuan by 2021.
, as of the close of trading on December 28, Hengrui Pharma closed down 3.49 per cent at Rmb111bn/share, with a market capitalisation of Rmb591.8bn, according to Wind Financial Terminals.
。